| Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? Y Mehellou, E De Clercq Journal of medicinal chemistry 53 (2), 521-538, 2010 | 507 | 2010 |
| The ProTide Prodrug Technology: From the Concept to the Clinic: Miniperspective Y Mehellou, HS Rattan, J Balzarini Journal of medicinal chemistry 61 (6), 2211-2226, 2017 | 334 | 2017 |
| Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells Y Mehellou, J Balzarini, C McGuigan ChemMedChem: Chemistry Enabling Drug Discovery 4 (11), 1779-1791, 2009 | 304 | 2009 |
| The CUL3–KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt … A Ohta, FR Schumacher, Y Mehellou, C Johnson, A Knebel, TJ Macartney, ... Biochemical Journal 451 (1), 111-122, 2013 | 244 | 2013 |
| MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases BM Filippi, P De Los Heros, Y Mehellou, I Navratilova, R Gourlay, M Deak, ... The EMBO journal 30 (9), 1730-1741, 2011 | 159 | 2011 |
| SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation JO Thastrup, FH Rafiqi, AC Vitari, E Pozo-Guisado, M Deak, Y Mehellou, ... Biochemical Journal 441 (1), 325-337, 2012 | 155 | 2012 |
| Nucleoside phosphate and phosphonate prodrug clinical candidates: Miniperspective PJ Thornton, H Kadri, A Miccoli, Y Mehellou Journal of medicinal chemistry 59 (23), 10400-10410, 2016 | 133 | 2016 |
| Niclosamide, a drug with many (re) purposes H Kadri, OA Lambourne, Y Mehellou ChemMedChem 13 (11), 1088-1091, 2018 | 103 | 2018 |
| Kinetin riboside and its ProTides activate the Parkinson’s disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization L Osgerby, YC Lai, PJ Thornton, J Amalfitano, CS Le Duff, I Jabeen, ... Journal of medicinal chemistry 60 (8), 3518-3524, 2017 | 94 | 2017 |
| BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain M Salim, TJ Knowles, AT Baker, MS Davey, M Jeeves, P Sridhar, J Wilkie, ... ACS chemical biology 12 (10), 2631-2643, 2017 | 73 | 2017 |
| The anthelmintic drug niclosamide and its analogues activate the Parkinson's disease associated protein kinase PINK1 E Barini, A Miccoli, F Tinarelli, K Mulholland, H Kadri, F Khanim, ... Chembiochem 19 (5), 425-429, 2018 | 61 | 2018 |
| Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism Y Mehellou, R Valente, H Mottram, E Walsby, KI Mills, J Balzarini, ... Bioorganic & Medicinal Chemistry 18 (7), 2439-2446, 2010 | 60 | 2010 |
| The ProTide prodrug technology: where next? AS Alanazi, E James, Y Mehellou ACS medicinal chemistry letters 10 (1), 2-5, 2018 | 57 | 2018 |
| Organometallic nucleoside analogues with ferrocenyl linker groups: synthesis and cancer cell line studies HV Nguyen, A Sallustrau, J Balzarini, MR Bedford, JC Eden, N Georgousi, ... Journal of Medicinal Chemistry 57 (13), 5817-5822, 2014 | 57 | 2014 |
| Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C‐terminal Domains MA AlAmri, H Kadri, LJ Alderwick, NS Simpkins, Y Mehellou ChemMedChem 12 (9), 639-645, 2017 | 55 | 2017 |
| The protides boom Y Mehellou ChemMedChem 11 (11), 1114-1116, 2016 | 55 | 2016 |
| An investigation into the anti-HIV activity of 2′, 3′-didehydro-2′, 3′-dideoxyuridine (d4U) and 2′, 3′-dideoxyuridine (ddU) phosphoramidate ‘ProTide’derivatives Y Mehellou, J Balzarini, C McGuigan Organic & Biomolecular Chemistry 7 (12), 2548-2553, 2009 | 46 | 2009 |
| Synthesis and Biological Evaluation of (E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 … MS Davey, R Malde, RC Mykura, AT Baker, TE Taher, CS Le Duff, ... Journal of medicinal chemistry 61 (5), 2111-2117, 2018 | 44 | 2018 |
| Design, synthesis, and anti-HIV activity of 2′, 3′-didehydro-2′, 3′-dideoxyuridine (d4U), 2′, 3′-dideoxyuridine (ddU) phosphoramidate ‘ProTide’derivatives Y Mehellou, C McGuigan, A Brancale, J Balzarini Bioorganic & medicinal chemistry letters 17 (13), 3666-3669, 2007 | 43 | 2007 |
| Structural insights into the activation of MST3 by MO25 Y Mehellou, DR Alessi, TJ Macartney, M Szklarz, S Knapp, JM Elkins Biochemical and biophysical research communications 431 (3), 604-609, 2013 | 32 | 2013 |
